Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib

Cancer Genetics - Tập 260 - Trang 46-52 - 2022
Erin R. Rudzinski1, Jaclyn Hechtman2, Sinchita Roy-Chowdhuri3, Marion Rudolph4, Christina M. Lockwood5,6, Josh Silvertown7, Justyna Wierzbinska4, Kui Shen7, Ricarda Norenberg8, Hendrik Nogai9, David S. Hong3, Alexander Drilon10,11, Theodore W. Laetsch12
1Seattle Children’s Hospital, Seattle, WA, USA
2Memorial Sloan-Kettering Cancer Center, New York, NY, USA
3The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Bayer AG Pharmaceuticals, Berlin, Germany
5Seattle Children's Hospital, Seattle, WA, USA
6University of Washington, Seattle, WA, USA
7Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA
8Chrestos Concept GmbH & Co. KG, Essen, Germany
9Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland
10Memorial Sloan Kettering Cancer Center, New York, NY, USA
11Weill Cornell Medical College, New York, NY, USA
12The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Cancer Genetics

Tập 260

46-52

Thông tin tác giả